The 6-month persistence on SSRIs and associated economic burden

References

• Mojtabai R. Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom 2008;77:83-92
   PubMed Web of Science ®Google Scholar
• Paulose-Ram R, Safran MA, Jonas BS, et al. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf 2007;16:560-570
   PubMed Web of Science ®Google Scholar
• Beck CA, Patten SB, Williams JV, et al. Antidepressant utilization in Canada. Soc Psychiatry Psychiatr Epidemiol 2005;40:799-807
   PubMed Web of Science ®Google Scholar
• Brugha TS, Bebbington PE, Singleton N, et al. Trends in service use and treatment for mental disorders in adults throughout Great Britain. Br J Psychiatry 2004;185:378-384
   PubMed Web of Science ®Google Scholar
• Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003;326:1008
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA 2002;287:203-209
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-1475
   PubMed Web of Science ®Google Scholar
• Isacsson G, Boethius G, Henriksson S, et al. Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. J Affect Disord 1999;53:15-22
   PubMed Web of Science ®Google Scholar
• Milea D, Verpillat P, Guelfucci F, et al. Prescription patterns of antidepressants: findings from a US claims database. Curr Med Res Opin 2010;26:1343-1353
   PubMed Web of Science ®Google Scholar
• Greenberg P, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363-373
   PubMed Web of Science ®Google Scholar
• Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-162
   PubMed Web of Science ®Google Scholar
• Practice guideline for the treatment of patients with major depressive disorder revision. American Psychiatric Association. Am J Psychiatry 2000;157:1-45
   Google Scholar
• NICE (National Institute for Health and Clinical Excellence). Depression: Management of depression in primary and secondary care. National Clinical Practice Guideline Number 23 amended. 2007
   Google Scholar
• Gichangi A, Andersen M, Kragstrup J, et al. Analysing duration of episodes of pharmacological care: an example of antidepressant use in Danish general practice. Pharmacoepidemiol Drug Saf 2006;15:167-177
   PubMed Web of Science ®Google Scholar
• Olie JP, Elomari F, Spadone C, et al. Antidepressants consumption in the global population in France. Encephale 2002;28:411-417
   PubMed Web of Science ®Google Scholar
• Pietraru C, Barbui C, Poggio L, et al. Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. Eur J Clin Pharmacol 2001;57:605-609
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-973
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47
   PubMed Web of Science ®Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008;24:1987-2000
   PubMed Web of Science ®Google Scholar
• Bockting CL, ten Doesschate MC, Spijker J, et al. Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008;77:17-26
   PubMed Web of Science ®Google Scholar
• Hansen HV, Kessing LV. Adherence to antidepressant treatment. Expert Rev Neurother 2007;7:57-62
   PubMedGoogle Scholar
• Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr 2007;12:1-27
   PubMed Web of Science ®Google Scholar
• Esposito D, Wahl P, Daniel G, et al. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clin Ther 2009;31:644-656
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Adelin A, Patrick M, et al. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008;23:36-42
   PubMed Web of Science ®Google Scholar
• ten Doesschate MC, Bockting CL, Schene AH. Adherence to continuation and maintenance antidepressant use in recurrent depression. J Affect Disord 2009;115:167-170
   PubMed Web of Science ®Google Scholar
• Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825-1837
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-1341
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-131
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-184
   PubMed Web of Science ®Google Scholar
• Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59:268-275
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-329
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-137
   PubMed Web of Science ®Google Scholar
• Tournier M, Moride Y, Crott R, et al. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. J Affect Disord 2009;115:160-166
   PubMed Web of Science ®Google Scholar
• Wu E, Greenberg P, Yang E, et al. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008;24:2805-2813
   PubMed Web of Science ®Google Scholar
• Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008;24:2587-2595
   PubMed Web of Science ®Google Scholar